Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominique Tytgat

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|January 15, 2016
Addressing potential prior-data conflict when using informative priors in proof-of-concept studiesTimothy Mutsvari, Dominique Tytgat, Rosalind Walley
Pharmaceutical Statistics|March 16, 2017
Addressing potential prior-data conflict when using informative priors in proof-of-concept studiesTimothy Mutsvari, Dominique Tytgat, Rosalind Walley
Drug Metabolism Reviews|July 16, 2009
Physiologically based pharmacokinetics (PBPK)Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 23, 2016
Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam HydrolysisArmel Stockis, Shikiko Watanabe, André J Scheen, et al.
European Journal of Clinical Pharmacology|February 5, 2017
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseasesEric Helmer, Mark Watling, Emma Jones, et al.
British Journal of Clinical Pharmacology|January 17, 2007
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy malesMaria Laura Sargentini-Maier, Paul Rolan, John Connell, et al.
Nuclear Medicine and Biology|June 5, 2016
[(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2ASergio Estrada, Mark Lubberink, Alf Thibblin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 2, 2014
Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeysOlivier Barret, Jonas Hannestad, David Alagille, et al.
Epilepsia|December 15, 2015
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of actionJean-Marie Nicolas, Jonas Hannestad, Daniel Holden, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|January 15, 2016
Addressing potential prior-data conflict when using informative priors in proof-of-concept studiesTimothy Mutsvari, Dominique Tytgat, Rosalind Walley
Pharmaceutical Statistics|March 16, 2017
Addressing potential prior-data conflict when using informative priors in proof-of-concept studiesTimothy Mutsvari, Dominique Tytgat, Rosalind Walley
Drug Metabolism Reviews|July 16, 2009
Physiologically based pharmacokinetics (PBPK)Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 23, 2016
Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam HydrolysisArmel Stockis, Shikiko Watanabe, André J Scheen, et al.
European Journal of Clinical Pharmacology|February 5, 2017
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseasesEric Helmer, Mark Watling, Emma Jones, et al.
British Journal of Clinical Pharmacology|January 17, 2007
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy malesMaria Laura Sargentini-Maier, Paul Rolan, John Connell, et al.
Nuclear Medicine and Biology|June 5, 2016
[(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2ASergio Estrada, Mark Lubberink, Alf Thibblin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 2, 2014
Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeysOlivier Barret, Jonas Hannestad, David Alagille, et al.
Epilepsia|December 15, 2015
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of actionJean-Marie Nicolas, Jonas Hannestad, Daniel Holden, et al.
Pageof 1